How Tenaya Therapeutics, Inc. is positioning TN-401 against the limitations of current ARVC care
Could TN-401 change ARVC treatment strategy? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.
Why Pulse Biosciences’ 12-month nsPFA data matters in a PFA market dominated by Farapulse and Affera
Boston Scientific owns the PFA market. Pulse Biosciences just posted 90% one-year AF freedom. Is nanosecond PFA a real disruption or an acquisition target?
Is Abbott building the next integrated platform for complex heart rhythm treatment?
Abbott has PFA momentum, but rhythm care is becoming a platform battle. Can clinical data turn into durable adoption?
Can CARTOSOUND SONATA help Johnson & Johnson tighten its grip on electrophysiology workflow?
See how Johnson & Johnson is using CARTOSOUND SONATA and VARIPULSE to reshape electrophysiology workflow and arrhythmia care. Read more.
Johnson & Johnson’s early OMNYPULSE data show promise, but the real test lies ahead
Johnson & Johnson has presented 12-month pilot data from the OMNY-AF study evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation at the 2026 AF Symposium. The early pilot cohort reported high acute procedural success, no procedure-related adverse events, and a 12-month freedom from atrial fibrillation rate approaching 90 percent. The […]
Medtronic expands Affera platform with Sphere-360 catheter CE Mark and IDE trial kickoff
Medtronic’s Sphere-360 catheter earns CE Mark and begins U.S. IDE trial. Find out what this means for the future of pulsed field ablation.
What the first use of YorLabs’ ICE device tells us about cardiology imaging disruption
Find out how YorLabs’ FDA-cleared ICE platform could transform electrophysiology access and imaging economics in 2026.